Approximately 1,626 five-count sample bottles of Minolira (minocycline hydrochloride) extended-release tablets, 135 mg, have been voluntarily recalled. These physician samples were found to have failed dissolution specifications, meaning the medication may not dissolve at the correct rate as intended. This defect can interfere with how the drug is absorbed by the body, potentially affecting its effectiveness.
If the medication fails to dissolve properly, the patient may not receive the intended therapeutic dose of minocycline, which could result in a lack of treatment efficacy for the underlying condition. There have been no reported injuries or adverse events associated with this recall to date.
Contact healthcare provider and return product for refund.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.